Search hospitals > Illinois > Danville
Carle on Vermilion
Claim this profileDanville, Illinois 61832
Global Leader in Skin Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Cancer
Conducts research for Breast cancer
286 reported clinical trials
14 medical researchers
Summary
Carle on Vermilion is a medical facility located in Danville, Illinois. This center is recognized for care of Skin Cancer, Lung Cancer, Breast Cancer, Cancer, Breast cancer and other specialties. Carle on Vermilion is involved with conducting 286 clinical trials across 458 conditions. There are 14 research doctors associated with this hospital, such as Suparna Mantha, Vamsi K. Vasireddy, Maria T. Grosse-Perdekamp, and Kendrith Rowland, MD.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage I
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Suparna ManthaCarle Cancer Center5 years of reported clinical research
Studies Skin Cancer
Studies Stomach Cancer
35 reported clinical trials
78 drugs studied
Vamsi K. VasireddyCarle Cancer Center3 years of reported clinical research
Expert in Skin Cancer
Expert in Cancer
31 reported clinical trials
56 drugs studied
Maria T. Grosse-PerdekampCarle Cancer Center3 years of reported clinical research
Expert in Breast Cancer
Studies Breast cancer
31 reported clinical trials
62 drugs studied
Kendrith Rowland, MDCarle Cancer Center8 years of reported clinical research
Studies Skin Cancer
Studies Breast Cancer
30 reported clinical trials
61 drugs studied
Clinical Trials running at Carle on Vermilion
Skin Cancer
Breast Cancer
Lung Cancer
Bladder Cancer
Kidney Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Cancer
Breast cancer
Squamous Cell Carcinoma
Immunotherapy With or Without Surgery
for Kidney Cancer
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Surgery to remove the kidney, called a nephrectomy, is also considered standard of care; however, doctors who treat kidney cancer do not agree on its benefits. It is not yet known if the addition of surgery to an immunotherapy-based drug combination works better than an immunotherapy-based drug combination alone in treating patients with kidney cancer.
Recruiting2 awards Phase 316 criteria
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Carle on Vermilion?
Carle on Vermilion is a medical facility located in Danville, Illinois. This center is recognized for care of Skin Cancer, Lung Cancer, Breast Cancer, Cancer, Breast cancer and other specialties. Carle on Vermilion is involved with conducting 286 clinical trials across 458 conditions. There are 14 research doctors associated with this hospital, such as Suparna Mantha, Vamsi K. Vasireddy, Maria T. Grosse-Perdekamp, and Kendrith Rowland, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.